CPHI Earnings Date: Nov 11, 2026 (Estimated) — China Pharma Holdings, Inc.
AMEX · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is CPHI's next earnings date?
China Pharma Holdings, Inc. (CPHI) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company.
How did CPHI do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), China Pharma Holdings, Inc. posted EPS of -$0.04. Revenue was $948,340. The stock's 1-day post-earnings move was -4.4%.
How much does CPHI stock move after earnings?
Over the last 8 reports the stock moved an average of 6.8% (up or down) in the day after earnings.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | — | -0.04 | — | $948,340 | — | -4.42% | -13.27% | -35.34% |
| 2026-05-15 | Q1 2026 | — | -0.04 | — | $983,536 | — | -28.43% | -26.95% | -24.80% |
| 2026-04-01 | Q4 2025 | — | -0.17 | — | $1.2M | — | -1.56% | +2.34% | -17.61% |
| 2025-11-12 | Q3 2025 | — | -0.17 | — | $756,217 | — | -2.31% | -1.03% | -0.13% |
| 2025-03-31 | Q4 2024 | — | -0.04 | — | $1.1M | — | -6.88% | -50.59% | -18.28% |
| 2024-11-13 | Q3 2024 | — | -0.06 | — | $1.1M | — | -3.16% | -5.19% | -12.55% |
| 2024-08-14 | Q2 2024 | — | -0.09 | — | $924,943 | — | +3.84% | +14.11% | +29.68% |
| 2024-05-15 | Q1 2024 | — | -0.07 | — | $1.4M | — | +3.78% | -1.19% | -19.48% |
Showing last 8 quarters.